Manufactures agrochemical active ingredients and intermediates, selling through two business lines: an Enterprise segment that markets its own crop protection products, and a Contract Manufacturing / CDMO business that makes intermediates and technical-grade molecules for global agrochemical customers. Geographically, exports dominate the mix — outside India contributed 68.4% of segment revenue at Rs 258.55 cr, while within India contributed 31.6% at Rs 119.60 cr. According to the FY26 disclosures, CDMO contributed 52% of sales and exports 62%. Cost structure is raw-material intensive at 60.3% of revenue, with employees at 14.0%, other operating expenses at 20.4% and depreciation at 10.0%. The company is a subsidiary of Godrej Agrovet, which holds 67.03%. FY26 closed with revenue of Rs 448.15 cr, a net loss of Rs 80.88 cr, and EBITDA barely above break-even after a prior-year loss. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Outside India (exports) (68%), Within India (domestic) (32%), CDMO / Contract Manufacturing (52%), Enterprise (proprietary). Asset-heavy agrochemical manufacturer, export-oriented, currently loss-making at the net level but at EBITDA break-even
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 677 | 628 | 458 | 381 | 448 |
| EBITDA (ex other income) | 154 | 76 | (6) | (66) | (7) |
| margin % | 22.8 | 12.1 | (1.3) | (17.4) | (1.5) |
| Owners' profit | 90 | 26 | (47) | (135) | (81) |
| EPS, as reported (₹) | 45.87 | 13.04 | (23.93) | (68.71) | (37.79) |
| ROE % · ROCE % | 22.7 · 32.1 | 6.1 · 12.3 | (12.7) · (6.3) | (57.3) · (20.2) | (20.7) · (10.5) |
| Debt / equity (x) | 0.70 | 0.81 | 1.34 | 2.36 | 1.15 |
| Cash from operations | 24 | 75 | 10 | (8) | (81) |
| Capex | (104) | (117) | (135) | (22) | (6) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 99 | 94 | 213 | 91 | 74 | 125 | 159 | 84 |
| Profit before tax | (39) | (25) | (41) | (33) | (24) | (16) | (8) | (19) |
| Net profit | (39) | (40) | (56) | (33) | (24) | (16) | (8) | (19) |
| EPS (₹) | (19.66) | (20.59) | (28.79) | (16.85) | (11.35) | (7.04) | (3.48) | (8.40) |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| UPL LIMITED | 48,414 | 23.7 | 1.17 | 6.5 | 5.4 | 5.5 | 6.0 | 16.3 |
| PI INDUSTRIES LTD | 34,337 | 29.4 | 3.06 | 16.2 | 11.8 | 14.5 | 8.0 | 25.3 |
| SUMITOMO CHEM INDIA LTD | 23,762 | 41.0 | 7.00 | 29.6 | 16.0 | 20.8 | 4.1 | 28.9 |
| BAYER CROPSCIENCE LTD | 17,895 | 26.0 | 6.03 | — | 23.2 | 27.3 | — |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 11 Sept 2026 · Astec LifeSciences replies to NSE query on unusual price movement | regulatory legal | medium | — | — |
| 10 Sept 2026 · NSE seeks clarification on significant price movement in Astec LifeSciences | regulatory legal | medium | — | — |
| 9 Sept 2026 · Astec LifeSciences responds to NSE query on unusual trading volume | regulatory legal | medium | — | — |
| 8 Sept 2026 · NSE seeks clarification from Astec LifeSciences on unusual trading volume | compliance | medium | — | — |
| 1 Aug 2026 · Astec LifeSciences Q1 FY27 loss narrows YoY to Rs 18.71 cr | compliance | minimal | — | — |
| 31 Jul 2026 · Astec LifeSciences 32nd AGM: All 3 resolutions passed with near-unanimous votes | board shareholder meetings | low | — | — |
| 31 Jul 2026 · Astec LifeSciences 32nd AGM held - all 3 resolutions passed with over 99.99 percent approval | board shareholder meetings | medium | — | — |
| 31 Jul 2026 · 32nd AGM concludes; all 3 resolutions passed with over 99.99 percent majority | board shareholder meetings | medium | — | — |
| 31 Jul 2026 · 32nd AGM: All 3 resolutions pass with near-unanimous support; FY26 losses narrow | board shareholder meetings | medium | — | — |
| 31 Jul 2026 · Astec LifeSciences Q1 FY27: Revenue down 8%, EBITDA at breakeven | compliance | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|
| 22.7 |
| SHARDA CROPCHEM LTD. | 6,910 | 11.0 | 2.20 | 5.7 | 21.7 | 25.2 | 17.1 | 20.5 |
| DHANUKA AGRITECH LTD | 4,359 | 14.9 | 3.11 | 9.7 | 21.2 | 27.0 | 12.7 | 27.4 |
| RALLIS INDIA LTD | 3,833 | 23.9 | 2.26 | 12.9 | 9.7 | 12.5 | — | 0.9 |
| NACL INDUSTRIES LIMITED | 3,709 | 310.4 | 5.43 | 45.4 | 0.7 | 1.4 | 5.9 | 11.3 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/B | 4.0 | 2.4 | 23 of 28 | 19% |
| ROCE | (18.3) | 12.5 | 27 of 29 | 7% |
| ROE | (20.7) | 9.2 | 26 of 28 | 7% |
| Debt / Equity | 1.1 | 0.3 | 26 of 29 | 11% |
| EBITDA margin | 0.1 | 14.8 | 25 of 28 | 11% |
| Revenue growth | (8.3) | (0.8) | 16 of 28 | 44% |
| Profit growth | 43.4 | 18.1 | 11 of 28 | 63% |
| Market cap | 1553 | 1540 | 14 of 29 | 54% |
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
